Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Integra LifeSciences (NASDAQ:IART) released its earnings results on Monday. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. Integra LifeSciences had a return on equity of 13.95% and a net margin of 1.51%. The business had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the previous year, the business earned $0.71 earnings per share. Integra LifeSciences’s quarterly revenue was up 9.7% on a year-over-year basis.

Integra LifeSciences Stock Down 0.9 %

Shares of NASDAQ IART traded down $0.22 during mid-day trading on Wednesday, reaching $24.81. 3,176,123 shares of the company’s stock traded hands, compared to its average volume of 1,160,863. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $46.09. The stock has a market cap of $1.96 billion, a P/E ratio of 50.06, a PEG ratio of 1.12 and a beta of 1.11. The business has a 50-day simple moving average of $29.67 and a 200 day simple moving average of $33.52.

Wall Street Analysts Forecast Growth

IART has been the subject of several recent analyst reports. BTIG Research downgraded Integra LifeSciences from a “neutral” rating to a “sell” rating and set a $22.00 price objective for the company. in a report on Tuesday. Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 7th. JMP Securities lowered their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday. Morgan Stanley lifted their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Finally, StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and a consensus target price of $29.25.

Insider Activity at Integra LifeSciences

In related news, Chairman Stuart Essig bought 52,641 shares of the company’s stock in a transaction dated Thursday, May 23rd. The shares were bought at an average price of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the acquisition, the chairman now directly owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is owned by insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.